Organized by the Spanish Society of Immunology (SEI)
Thursday, September 29th (9h30-11h00)
When the journal Science named
Cancer Immunotherapy as "breakthrough of the year 2013" it did
nothing but to confirm and sanction a reality that already existed. Less than
three years after this distinction we are witnessing an explosion of new therapeutic
antibodies and cutting edge methods focused on increasing the success of
cell-based therapy. In this symposium we will review how targeting an
inhibitory receptor has a relevant impact in the efficacy of therapeutic
antibodies. In addition, we will discuss the current thinking and future
directions of the Chimeric Antigen Receptor (CAR) T-cell programme for cancer
treatment that is being implemented in the University College London; how to
identify and expand T cells from blood that are antigen-specific for tumor
cells and their use in immunotherapy; and finally, the present and future of a
class of innate lymphocytes, termed natural killer (NK) cells, in adoptive cell
therapy for cancer treatment.
- África González Fernández: President, SPANISH
SOCIETY OF IMMUNOLOGY (SEI) / Director, BiOMEDICAL RESEARCH CENTER
(CINBIO) & Professor in Immunology, UNIVERSITY OF VIGO (Spain).
- Mark S. Cragg: Professor in Immunotherapy, Antibody &
Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, UNIVERSITY OF
SOUTHAMPTON-SOUTHAMPTON GENERAL HOSPITAL (United Kingdom). “IIB
or not IIB: Contrasting roles of the inhibitory FcyRIIB in regulating different
classes of antibody immunotherapy”.
- Claire Roddie: Clinician scientist, Research Department of Haematology,
Cancer Institute, Faculty of Medical Sciences, UNIVERSITY COLLEGE OF LONDON
(United Kingdom). “CAR T-cell therapy for haematological malignancy”.
- Alena Gros: Principal Investigator, Tumour Immunology and
Immunotherapy Group, VALL d’HEBRON INSTITUTE OF ONCOLOGY - VHIO (Spain). “Identification and isolation of neoantigen-specific
lymphocytes in peripheral blood of cancer patients”.
- Francisco Borrego: Ikerbasque Research Professor, Immunopathology Group,
BIOCRUCES HEALTH RESEARCH INSTITUTE OF BARAKALDO (Spain). “NK
cell-based cancer Immunotherapy”
- Julio Castro: CEO, PALOBIOFARMA (Spain). “Targeting adenosine modulation in the tumor microenvironment: A novel
approach in cancer immunotherapy”